CAS · 503612-47-3
Product Overview
Apixaban is a high-purity a-api supplied for industrial and specialty chemical applications. Contact our team for specifications, packaging options and lead times.
Product Specifications
| Appearance | White powder |
|---|---|
| Identification by IR | IR spectrum should concordant with working standard |
| Identification by HPLC | Retention time should match that in the chromatogram |
| Loss on drying | 1.0% max |
| Water | 1.0% max |
| Ignited residue | 0.1% max |
| Heavy metal | 20 ppm max |
| Single impurity | 0.1% max |
| Total impurity | 1.0% max |
| Purity (HPLC) | 99.5% min |
| Triethylamine | 0.5% max |
| N,N-dimethylformamide | 0.08% max |
| Morpholine | 0.1% max |
| Methanol | 0.3% max |
| Ethanol | 0.5% max |
| Ethyl Acetate | 0.5% max |
| Trimethyl Orthoformate | 0.1% max |
Applications
Apixaban is widely used in the pharmaceutical and medical research fields as an orally active anticoagulant belonging to the class of direct factor Xa inhibitors. It is applied in clinical settings to reduce the risk of thromboembolic events by inhibiting the activity of factor Xa, a key enzyme in the coagulation cascade responsible for thrombin generation and clot formation. In research environments, Apixaban serves as a reference compound for studying coagulation pathways, anticoagulant mechanisms, and drug–protein interactions relevant to thrombosis and hemostasis. It is also used in comparative studies evaluating newer anticoagulants, structural optimization efforts for next-generation factor Xa inhibitors, and investigations into drug transport, metabolism, and pharmacokinetics. Its predictable anticoagulant effect makes it a reliable tool in both preclinical and mechanistic studies related to thrombosis management and drug development.
Benefits
Apixaban offers several advantages that contribute to its widespread use and scientific interest. Its high selectivity for factor Xa allows targeted anticoagulation without affecting other components of the coagulation cascade, supporting a more controlled therapeutic profile. The compound exhibits predictable pharmacokinetics and pharmacodynamics, which helps reduce variability and simplifies research involving anticoagulant modeling and biomarker analysis. Its oral bioavailability provides convenience in clinical practice and facilitates in vivo experimental designs in research settings. Apixaban has fewer known food and drug interactions compared with some traditional anticoagulants, improving study consistency and reducing confounding variables in research. Additionally, its well-characterized structure and mechanism of action make it an ideal benchmark compound for designing and evaluating new anticoagulant candidates.
Conclusion
Apixaban is an important anticoagulant and research compound with targeted factor Xa inhibition, broad application in clinical practice, and significant value in scientific studies of thrombosis and coagulation. Its selectivity, predictable behavior, and structural clarity support reliable therapeutic use and enable detailed investigations into coagulation biology and drug discovery. Overall, Apixaban remains a key molecule in the advancement of anticoagulant therapies and mechanistic research related to cardiovascular and hematological health.
Previous
Ruxolitinib Phosphate丨CAS 1092939-17-7
Next